MedPath

Danazol

Generic Name
Danazol
Brand Names
Cyclomen
Drug Type
Small Molecule
Chemical Formula
C22H27NO2
CAS Number
17230-88-5
Unique Ingredient Identifier
N29QWW3BUO
Background

A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.

Indication

For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.

Associated Conditions
Endometriosis, Fibrocystic Disease of Breast, Hereditary Angioedema (HAE), Refractory immune thrombocytopenia
Clinical Trials
Related News

The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Phase 2
Recruiting
Conditions
Immune Thrombocytopenia
Interventions
First Posted Date
2023-12-20
Last Posted Date
2023-12-20
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
124
Registration Number
NCT06176911
Locations
🇨🇳

Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China

Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia

Phase 2
Recruiting
Conditions
Immune Thrombocytopenia
Interventions
First Posted Date
2023-05-10
Last Posted Date
2023-06-13
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
216
Registration Number
NCT05852847
Locations
🇨🇳

The Sixth Medical Center of PLA General Hospital, Beijing, China

🇨🇳

Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China

🇨🇳

Beijing Friendship Hospital, Beijing, China

and more 7 locations

Comparisons of the Therapeutic Effects of Dienogest and Danazol on Endometriosis

Phase 3
Recruiting
Conditions
Endometriosis
Interventions
First Posted Date
2023-01-26
Last Posted Date
2023-03-29
Lead Sponsor
Far Eastern Memorial Hospital
Target Recruit Count
120
Registration Number
NCT05697471
Locations
🇨🇳

Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Banqiao, New Taipei, Taiwan

The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia

Phase 2
Conditions
Immune Thrombocytopenia
Interventions
First Posted Date
2022-08-09
Last Posted Date
2022-08-09
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
228
Registration Number
NCT05494307

The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Phase 2
Conditions
Immune Thrombocytopenia
Interventions
Drug: TAC
First Posted Date
2022-07-22
Last Posted Date
2022-07-22
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
120
Registration Number
NCT05471050
Locations
🇨🇳

Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China

The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Phase 2
Conditions
Immune Thrombocytopenia
Blood Coagulation Disorders
Thrombocytopenia
Physiological Effects of Drugs
Interventions
First Posted Date
2022-04-29
Last Posted Date
2022-04-29
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
120
Registration Number
NCT05353673
Locations
🇨🇳

Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing, China

The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Phase 2
Conditions
ITP
Immune Thrombocytopenia
Interventions
First Posted Date
2022-03-15
Last Posted Date
2022-05-02
Lead Sponsor
Peking University People's Hospital
Target Recruit Count
120
Registration Number
NCT05281068
Locations
🇨🇳

Zhuo-Yu An, Beijing, China

🇨🇳

Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, China

Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes

Phase 2
Recruiting
Conditions
Myelodysplastic Syndromes (MDS)
Interventions
Drug: Sodium Valproate, Bezafibrate, Medroxyprogesterone
First Posted Date
2021-08-10
Last Posted Date
2023-10-03
Lead Sponsor
Prof. Janet Dunn
Target Recruit Count
120
Registration Number
NCT04997811
Locations
🇬🇧

Royal Hampshire County Hospital, Hampshire Hospitals NHS Foundation Trust, Winchester, Hampshire, United Kingdom

🇬🇧

Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Hucknall Road, Nottingham, Nottinghamshire, United Kingdom

🇬🇧

Royal Cornwall Hospital NHS Trust, Truro, Cornwall, United Kingdom

and more 16 locations

Danazol for Treatment of Cytopenias in Patients With Cirrhosis

Phase 2
Recruiting
Conditions
Cirrhosis, Liver
Cytopenia
Interventions
First Posted Date
2021-05-05
Last Posted Date
2023-04-21
Lead Sponsor
University of Southern California
Target Recruit Count
10
Registration Number
NCT04873102
Locations
🇺🇸

Keck Hosital of USC, Los Angeles, California, United States

PRETELL: PREvention of TELomere-related Complications After Lung Transplant

Phase 1
Withdrawn
Conditions
Lung Transplant
Short Telomere Length
Interventions
Drug: Placebo
First Posted Date
2021-03-19
Last Posted Date
2023-02-15
Lead Sponsor
Brigham and Women's Hospital
Registration Number
NCT04807309
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy